This trial is active, not recruiting.

Conditions epilepsy, generalized tonic-clonic seizures
Treatment brain sentinel seizure detection and warning system
Phase phase 3
Sponsor Brain Sentinel
Start date January 2013
End date September 2017
Trial size 20 participants
Trial identifier NCT02555410, 3.01P


This is a phase III, pilot, prospective study of an Electromyography (EMG) based seizure detection system for detecting Generalized Tonic-Clonic Seizures (GTCS) in the home.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
To test the usability of the Brain Sentinel Seizure Detection and Warning System(also known as the SPEAC system) in a patient home setting.
brain sentinel seizure detection and warning system SPEAC System
A sEMG based automated seizure detection and warning system worn on the biceps

Primary Outcomes

Test the function of the system including ability to acquire EMG signal, analyze and successfully transmit the analysis to the base station, and identify and transmit all alert conditions.
time frame: up to 1 month

Secondary Outcomes

Compare the accuracy of the EMG based system's log to the subject's seizure diary
time frame: up to one month

Eligibility Criteria

Male or female participants from 2 years up to 99 years old.

Inclusion Criteria: 1. Subject has a history of GTC seizures, either primary GTC or partial onset seizures with secondary generalization. 2. Male or female between the ages of 2-99. 3. Has an upper arm circumference which is adequate for proper fit of the EMG monitor (at least 14cm). 4. Be able to tolerate wearing the device on the upper arm. 5. If female and of childbearing potential, has a negative pregnancy test. 6. Can understand and sign written informed consent, or will have a parent or a legally authorized representative (LAR) who can do so, prior to the performance of any study assessments. 7. Subject and/or Primary Caregiver must be competent to follow all study procedures. 8. Is able to read, speak and understand English. Exclusion Criteria: 1. Does not have a documented history of generalized seizures. 2. The subject's upper arm circumference not adequate for proper fit of the EMG monitor (less than 14cm) 3. Pregnant female 4. Subject/Caregiver is unable to provide consent. 5. Subject/Caregiver is not competent to follow home study procedures. 6. The subject is homeless or in a home without a power supply.

Additional Information

Official title A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients
Principal investigator Jose E. Cavazos, MD, PhD
Description The Brain Sentinel™ Seizure Detection and Warning System is intended for monitoring children and adults with a history or significant risk of generalized tonic-clonic seizures in the home or healthcare facilities, during the titration or withdrawal of anti-epileptic drugs, and for continuous monitoring (night time or any other time of day) of individuals due to their history or risk of generalized tonic-clonic seizures. The device will withstand activities of daily living including showers and sleep.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Brain Sentinel.